The North American DNA Vaccine market is anticipated to grow at a CAGR 42.8% during the forecast period. North America is creating a significant opportunity for the DNA vaccination market. Several types of research have been conducted by medical research centers in the region. For instance, In Dec 2017, the National Institute of Allergy and Infectious Diseases (NIAID), a part of NIH (National Institute of Health) has developed a Gene-based Zika vaccine. The center developed two different plasmids for clinical testing, including VRC5283 and VRC5288. In clinical trials, it was found that vaccinations are safe; however, some participants experienced swelling, redness and inflammation at the injection site.
Visit for Global DNA Vaccine Market Report at: https://www.omrglobal.com/industry-reports/dna-vaccines-market
Moreover, increasing funding for activities for DNA vaccinations is also primarily driving the DNA vaccination market in North America. As an instance, In Jan 2018, Bill and Melinda Gates Foundation have granted $1.4 million to the Wistar Institute (Philadelphia) to develop a synthetic DNA-based vaccine for malaria.
Further, the North American market is analyzed on the basis of the countries that are contributing significantly towards the growth of the market. The North American market is further bifurcated into the United States and Canada. North American DNA vaccine is further segmented into type, technology and application. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery. Based on application, the market is segmented into oncology, infectious disease and others.
The key market player that are active in the market includes Arbutus Biopharma Corp., Dendreon Pharmaceuticals LLC, GE Healthcare, GlaxoSmithKline PLC., Green Cross Corp., Innovio Biomedical Corp., Immunomic Therapeutics, Merck & Co., Pfizer Inc., Protein Sciences Corp., Qed Biosciences Inc., Sanofi Inc., Tolerion Inc., Vical Inc. and Zoetis Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology
The market study of the North American DNA Vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Competitive Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.1. Opportunities
5. Market Segmentation
5.1. North American DNA Vaccine Market by Type
5.1.1. Animal DNA Vaccine
5.1.2. Human DNA Vaccine
5.2. North American DNA Vaccine Market by Technology
5.2.1. Plasmid DNA Vaccine
5.2.2. Plasmid DNA Delivery
5.3. North American DNA Vaccine Market by Application
5.3.1. Oncology
5.3.2. Infectious Disease
5.3.3. Others
6. Regional Analysis
6.1. North American
6.1.1 United States
6.1.2 Canada
7 Company Profiles
7.1 Arbutus Biopharma Corp.
7.2 Dendreon Pharmaceuticals LLC
7.3 GE Healthcare
7.4 Glaxosmithkline PLC.
7.5 Green Cross Corp.
7.6 Immunomic Therapeutics
7.7 Innovio Biomedical Corp.
7.8 Merck & Co.
7.9 Pfizer Inc.
7.10 Protein Sciences Corp.
7.11 Qed Biosciences Inc.
7.12 Sanofi Inc.
7.13 Tolerion Inc.
7.14 Vical Inc.
7.15 Zoetis Inc.
1. NORTH AMERICAN DNA VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
2. NORTH AMERICAN DNA VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)
3. NORTH AMERICAN DNA VACCINE MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2018-2025 ($ MILLION)
4. NORTH AMERICAN DNA VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)
1. NORTH AMERICAN DNA VACCINE MARKET SHARE BY COUNTRY, 2018 VS 2025 (%)
2. NORTH AMERICAN DNA VACCINE MARKET SHARE BY TYPE, 2018 VS 2025 (%)
3. NORTH AMERICAN DNA VACCINE MARKET SHARE BY TECHNOLOGY, 2018 VS 2025 (%)
4. NORTH AMERICAN DNA VACCINE MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)
5. THE US DNA VACCINE MARKET SIZE, 2018-2025 ($ MILLION)
6. CANADA DNA VACCINE MARKET SIZE, 2018-2025 ($ MILLION)